US officials worried about Chinese control of American drug supply
Yisheng Biopharma, a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, said that its new rabies vaccine production facility has received a Pharmaceutical GMP Certificate from the China National Medical Products Administration (NMPA) for production of its Yisheng Junan product, the first lyophilized rabies vaccine without an aluminum adjuvant produced in China for medical use. The Yisheng Junan vaccine has been used for more than 15 years by tens of millions of individuals, and represents a significant share of the market for preventive vaccines against rabies infection. The vaccine has demonstrated effective protection, contributing to the fight against rabies infection. The newly constructed state-of-art production facility is operated by the Liaoning Yisheng Biopharma subsidiary. Invested about $60 million to build two new vaccine production facilities
Abivax's share price has surged more than 160% in a little more than one trading session. Investors drove up the stock on the back of news regarding its HIV collaboration, sparking a chain of events that saw the share prices of a clutch of biotech stocks surge on the Paris exchange.